GHAPPcast

In this episode, Jordan Mayberry, PA-C from UT Southwestern Medical Center, discusses how newly approved therapies are transforming the management of cholestatic pruritus in Primary Biliary Cholangitis (PBC). With pruritus being one of the most challenging symptoms for PBC patients, these emerging treatments offer a targeted approach to improving patient quality of life. As PBC patients often stru...

Live from the GHAPP 2024 Conference in Washington, D.C., Dr. Renee Pozza, NP (Southern California GI & Liver Centers) and Allysa Saggese, NP (Weill Cornell Medicine, Manhattan) discuss the latest FDA-approved therapies for Primary Biliary Cholangitis (PBC) and how they fit into the evolving treatment landscape. With new medications offering both biochemical improvements and symptom relief, par...

Thank you to Madrigal for your support of this Medication Review Video Module. In this Medication Review Video Module, Whitney Steinmetz, NP, provides an in-depth discussion on the clinical profile of Retam (Resd) for Metabolic-Associated Steatohepatitis (MASH) with moderate to advanced F2 or F3 fibrosis. While Retam is not currently FDA-approved for patients with cirrhosis, ongoing trials are eva...

Thank you to Madrigal for your support of this FAQ Video Module. In this FAQ Video Module, Jonathan Yeh, PA, from Columbia University Irving Medical Center, discusses the evolution of Metabolic Dysfunction-Associated Steatohepatitis (MASH) diagnosis and fibrosis staging. Formerly known as NASH, MASH was traditionally diagnosed through liver biopsy, but non-invasive testing (NITs) is now widely acc...

Thank you to Madrigal for your support of this FAQ Video Module. In this FAQ Video Module, Corrie Berk, NP, Director of Hepatology and Transplant Outreach Programs at the Texas Liver Institute, discusses the serious consequences of untreated Metabolic Dysfunction-Associated Steatohepatitis (MASH) and how Advanced Practice Providers (APPs) can play a crucial role in patient education and early inte...

Thank you to Madrigal for your support of this Medication Review Video Module. In this Medication Review Video Module, Robin Soto, NP, from UC San Diego Health Hepatology, provides an in-depth look at the mechanism of action of Resmetirom, the first and only FDA-approved drug for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in adults with F2, F3, or mild to moderate fib...

Thank you to Madrigal for your support of this FAQ Video Module. In this FAQ Video Module, Corrie Berk, NP, Director of Hepatology and Transplant Outreach Programs at the Texas Liver Institute, answers key questions about Metabolic Dysfunction-Associated Steatohepatitis (MASH)—a progressive liver disease that was previously known as Non-Alcoholic Steatohepatitis (NASH). MASH is the inflammatory fo...

Thank you to Madrigal for your support of this Journal Club Video Module. In this Journal Club Video Module, Lisa Richards, NP, a hepatology specialist with over 20 years of experience at UC San Diego Health, presents the pivotal findings of the Phase 3 randomized controlled trial of Resmetirom for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with liver fibrosis. Publis...

Thank you to Madrigal for your support of this GHAPPcast episode. In this GHAPPcast episode, Patrick Horne, NP, from the University of Florida, and April Morris, NP, from Richmond VA, discuss how to recognize the severity of MASH, identify at-risk patients, and implement early intervention strategies to prevent disease progression. MASH is strongly linked to metabolic dysfunction, making certain p...

Thank you to Ardelyx for your support of this FAQ Video Module. In this FAQ Video Module, Kim Orleck, PA-C, from Atlanta Gastroenterology Associates, discusses best practices to accelerate the process of identifying the right therapy for patients with Irritable Bowel Syndrome with Constipation (IBS-C). A timely and accurate diagnosis is the foundation for effective treatment, helping reduce unnece...

Thank you to Ardelyx for your support of this FAQ Video Module. In this episode, Kim Orleck, PA-C, discusses key strategies for evaluating treatment response in patients with IBS-C (Irritable Bowel Syndrome with Constipation). With multiple therapeutic options now available, it is essential for providers to take a patient-centered approach to ensure meaningful symptom improvement and treatment sat...

Thank you to Ardelyx for your support of this FAQ Video Module. In this FAQ Video Module, Kim Orleck, PA-C, from Atlanta Gastroenterology Associates, shares the most valuable resources for staying up to date on the latest approaches to managing IBS-C patients. As treatment strategies continue to evolve, leveraging evidence-based guidelines, professional conferences, industry expertise, and peer di...

Thank you to Boehringer Ingelheim for your support of this FAQ Video Module. Join Tedra Gray, NP, as she dives into what it means for a biosimilar to be interchangeable. Interchangeability is a key designation in the world of biosimilars, ensuring that these medications can be substituted for their reference products at the pharmacy level without the need for prescriber approval. Only a select few...

Thank you to Ardelyx for your support of this GHAPPcast episode. In this episode of GHAPPcast, the official podcast for Gastroenterology and Hepatology Advanced Practice Providers, host Christina Hanson, NP, is joined by Kim Kearns, NP, to explore the complex pathophysiology of IBS-C (Irritable Bowel Syndrome with Constipation) and the evolving neuromodulation strategies that enhance patient care....

Thank you to Boehringer Ingelheim for your support of this podcast. Welcome to GHAPPcast, the official podcast for gastroenterology and hepatology advanced practice providers. Hosted by Gabriella McCarty, a nurse practitioner at NorthShore Gastroenterology in Cleveland, this episode dives into a crucial topic—biosimilars from a patient’s perspective. As a founding member of GHAPP and a provider wi...

Thank you to Ardelyx for sponsoring this GHAPPcast episode!  In this episode of GHAPPcast, host Christina Hanson, FNP, alongside guest Kim Orleck, PA-C, dives into advanced strategies for diagnosing and managing IBS-C. They discuss the importance of the positive diagnostic strategy, ways to differentiate IBS-C from other conditions, and share valuable insights on how to optimize patient care...

Thank you to Boehringer Ingelheim for your support of this FAQ Video Module. Join Tedra Gray, NP, as she explains how biosimilars and generics play a crucial role in modern medicine, especially in fields like gastroenterology, rheumatology, and dermatology. She explains the key differences between biosimilars and generic medications, helping both healthcare providers and patients make informed tre...

Thank you to Ardelyx for your support of this FAQ Video Module. For years, the primary treatment options for irritable bowel syndrome with constipation (IBS-C) have been limited to secretagogues, offering varying doses and tolerability. However, a new mechanism of action (MOA) is now available, revolutionizing treatment choices for healthcare providers and patients alike. In this discussion, Kim O...

Thank you to Boehringer Ingelheim for your support of this podcast. In this episode of GHAPPcast, the official podcast for Gastroenterology and Hepatology Advanced Practice Providers, host Gabriella McCarty, NP, is joined by Tedra Gray, NP, to explore the role of biosimilars in GI treatment. They dive into the differences between biosimilars and generics, the cost savings associated with biosimila...

Join Dr. Nadege Gunn, from the 2024 Liver Connect Conference. In this special episode, she is joined by Elizabeth Coacher, PA, and Ann Moore, FNP, to discuss the management of NASH (Nonalcoholic Steatohepatitis), newly approved treatments, and the importance of clinical trials. They explore patient-centered care, lifestyle modifications, and non-invasive tests for identifying at-risk patients. Tun...

In our twelfth and final episode of the GHAPP & RhAPP biosimilar podcast series host Gabriella McCarty, NP, and guest Jamie Brogan, NP have an in-depth conversation about discussing biosimilars with patients. The learning objectives for this episode are to: Design methods to appropriately explain biosimilars to patients Address potential patient perceptions of biosimilars Devise methods to com...

Welcome to our eleventh episode of the GHAPP & RhAPP biosimilar podcast series! In the penultimate episode host Amanda Mixon, PA-C has an in-depth conversation with the incredible Naomi A. Amudala, CRNP, MSN,  about The Nocebo Effect. The learning objectives and goals for this episode are to: Define the nocebo effect Appraise nocebo effect research as it pertains to biosimilars Explain effecti...

In the tenth episode of the GHAPP & RhAPP biosimilar podcast series host Gabriella McCarty, NP-C, and guest Sharon Dudley-Brown PHD, FNP-BC, FAAN, FAANP discuss the practical use of biosimilars in Gastroenterology APP practice. The learning objectives for this episode are to: Interpret the AGA Biosimilars Roundtable meeting report and the Crohn’s & Colitis Foundation Biosimilar position st...

In the ninth episode of the GHAPP & RhAPP biosimilar podcast series host Amanda Mixon, PA-C, and guest Daric Mueller, PA-C discuss the practical use of biosimilars in rheumatology APP practice. The learning objectives for this episode are to: Interpret the ACR white paper on biosimilars in rheumatology Discuss the use of biosimilars in the treatment of rheumatic diseases Produce strategies for...

In our eighth episode of the GHAPP & RhAPP biosimilar podcast series host Gabriella McCarty, NP, and guest Gwen Cassidy, NP review the benefits of biosimilars. The learning objectives for this episode are to: Outline the cost savings of biosimilars for patients Summarize the cost savings for healthcare organizations Discuss  healthcare providers  feeling the pressure and burden of rising costs...